• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effect of atorvastatin co ‐treatment on inhibition of platelet activation by clopidogrel in patients with ischemic stroke
International Journal of Stroke,Volume 10, Issue 8, Page E90-E91, December 2015.
Source: International Journal of Stroke - November 18, 2015 Category: Neurology Source Type: research

Effect of atorvastatin co‐treatment on inhibition of platelet activation by clopidogrel in patients with ischemic stroke
Source: International Journal of Stroke - November 18, 2015 Category: Neurology Authors: Atsushi Mizuma, Kazuyuki Iijima, Saori Kohara, Mie Shimizu, Ryoko Imazeki, Tsuyoshi Uesugi, Yoichi Ohnuki, Shunya Takizawa Tags: Letter to the editor Source Type: research

Effect of atorvastatin co ‐treatment on inhibition of platelet activation by clopidogrel in patients with ischemic stroke
Source: International Journal of Stroke - November 17, 2015 Category: Neurology Authors: Atsushi Mizuma, Kazuyuki Iijima, Saori Kohara, Mie Shimizu, Ryoko Imazeki, Tsuyoshi Uesugi, Yoichi Ohnuki, Shunya Takizawa Tags: Letter to the editor Source Type: research

Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388)
DiscussionThe trial has recruited more than 50% of its target sample size (latest number: 2399) and is running in 104 sites in 4 countries. One‐third of patients presented with a transient ischemic attack.
Source: International Journal of Stroke - June 16, 2015 Category: Neurology Tags: Protocol Source Type: research

Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial
DiscussionThis paper and attachment describe the trial's statistical analysis plan, as developed from the protocol during recruitment and prior to unblinding of data. The statistical analysis plan contains design and methods for analyses, and unpopulated tables and figures for the primary and baseline publications. The data from the trial will provide the first large‐scale randomized evidence for the use of intensive antiplatelet therapy for preventing recurrence after acute stroke and transient ischemic attack.
Source: International Journal of Stroke - December 31, 2014 Category: Neurology Authors: Philip M. W. Bath, Katie Robson, Lisa J. Woodhouse, Nikola Sprigg, Robert Dineen, Stuart Pocock, Tags: Protocol Source Type: research

Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: a meta‐analysis of cohort studies and randomized controlled trials
ConclusionsIn acute ischemic stroke patients receiving intravenous recombinant tissue plasminogen activator therapy, prior antiplatelet agent use did not lead to a significant difference in functional outcome, although it significantly increased the risk of symptomatic intracranial hemorrhage. Recanalization rate was not different between two groups. In the subgroup analysis, prior clopidogrel mono therapy may not increase the risk of symptomatic intracranial hemorrhage, which will need further studies to confirm.
Source: International Journal of Stroke - December 25, 2014 Category: Neurology Authors: Xiding Pan, Yubing Zhu, Danni Zheng, Yukai Liu, Feng Yu, Jie Yang Tags: Review Source Type: research

Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open‐label, parallel‐group trial
DiscussionThe CSPS.com is expected to provide evidence indicating whether secondary IS prevention in high‐risk patients can be improved by using DAPT involving cilostazol.
Source: International Journal of Stroke - December 8, 2014 Category: Neurology Authors: Kazunori Toyoda, Shinichiro Uchiyama, Haruhiko Hoshino, Kazumi Kimura, Hideki Origasa, Hiroaki Naritomi, Kazuo Minematsu, Takenori Yamaguchi, Tags: Protocols Source Type: research

Effect of addition of clopidogrel to aspirin on subdural hematoma: meta‐analysis of randomized clinical trials
ConclusionsThe absolute rate of subdural hematoma during dual antiplatelet therapy is low, averaging 1·1 per 1000 patient‐years. Chronic treatment with clopidogrel plus aspirin significantly increases the risk of subdural hematoma compared with aspirin alone.
Source: International Journal of Stroke - December 1, 2014 Category: Neurology Authors: Majid F. Bakheet, Lesly A. Pearce, Robert G. Hart Tags: Research Source Type: research

Differences in ischemic and hemorrhagic recurrence rates among race‐ethnic groups in the PRoFESS secondary stroke prevention trial
ConclusionsWe found a significant difference in myocardial infarction and symptomatic intracerebral hemorrhage recurrence among different race‐ethnic groups. The risk of recurrent ischemic and hemorrhagic stroke was greater in Asians with high blood pressure.
Source: International Journal of Stroke - March 18, 2014 Category: Neurology Authors: Conrado J. Estol, Philip M. W. Bath, Philip B. Gorelick, Daniel Cotton, Renee Hebert Martin, Tags: Research Source Type: research

Effectiveness and safety of antiplatelet in stroke patients with end‐stage renal disease undergoing dialysis
ConclusionsAntiplatelet therapy, especially aspirin, still offers safe and effective treatment for ischemic stroke prevention in patients with end‐stage renal disease undergoing dialysis.
Source: International Journal of Stroke - February 1, 2014 Category: Neurology Authors: Chung‐Yu Chen, Kun‐Tai Lee, Charles Tzu‐Chi Lee, Wen‐Ter Lai, Yaw‐Bin Huang Tags: Research Source Type: research

Tissue kallikrein preventing the restenosis after stenting of symptomatic MCA atherosclerotic stenosis (KPRASS)
ConclusionAs our pilot study, tissue kallikrein would be expected to prevent the long‐term in‐stent restenosis after stenting of the symptomatic middle cerebral artery dramatically.
Source: International Journal of Stroke - December 21, 2013 Category: Neurology Authors: Wenya Lan, Fang Yang, Ling Liu, Qin Yin, Min Li, Zhuangli Li, Hongfei Sang, Gelin Xu, Minmin Ma, Zhizhong Zhang, Zhenguo Liu, Xinfeng Liu, Renliang Zhang Tags: Protocols Source Type: research

Platelet‐Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: Rationale and design
DiscussionAspirin is the most common antithrombotic given to patients with a stroke or transient ischemic attack, as it reduces the risk of subsequent stroke. This trial expects to determine whether more aggressive antithrombotic therapy with clopidogrel plus aspirin, initiated acutely, is more effective than aspirin alone.
Source: International Journal of Stroke - July 23, 2013 Category: Neurology Authors: S. Claiborne Johnston, J. Donald Easton, Mary Farrant, William Barsan, Holly Battenhouse, Robin Conwit, Catherine Dillon, Jordan Elm, Anne Lindblad, Lewis Morgenstern, Sharon N. Poisson, Yuko Palesch Tags: Protocols Source Type: research

Effect of addition of clopidogrel to aspirin on stroke incidence: Meta‐analysis of randomized trials
ConclusionsThis meta‐analysis demonstrates a substantial relative risk reduction in stroke by clopidogrel plus aspirin vs. aspirin alone that is consistent across different trial cohorts. Major haemorrhage is increased by dual antiplatelet therapy.
Source: International Journal of Stroke - May 22, 2013 Category: Neurology Authors: Santiago Palacio, Robert G. Hart, Lesly A. Pearce, David C. Anderson, Mukul Sharma, Lee A. Birnbaum, Oscar R. Benavente Tags: Research Source Type: research

Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study
ConclusionsEarly dual therapy with clopidogrel and aspirin reduces microembolic signals in patients with minor ischemic stroke or transient ischemic attack, without causing significant bleeding complications.
Source: International Journal of Stroke - March 12, 2013 Category: Neurology Authors: Alexander Y. Lau, Yudong Zhao, Christopher Chen, Thomas W. Leung, Jianhui Fu, Yining Huang, Nijasri C. Suwanwela, Zhao Han, Kay Sin Tan, Disya Ratanakorn, Hugh S. Markus, Ka Sing Wong, Tags: Clinical Trial Source Type: research